Compounds > moclobemide

moclobemide and 2h-benzo(a)quinolizin-2-ol, 2-ethyl-1,3,4,6,7,11b-hexahydro-3-isobutyl-9,10-dimethoxy-

moclobemide has been researched along with 2h-benzo(a)quinolizin-2-ol, 2-ethyl-1,3,4,6,7,11b-hexahydro-3-isobutyl-9,10-dimethoxy- in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19901 (33.33)18.7374
1990's2 (66.67)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Cesura, AM; Colzi, A; d'Agostini, F; Da Prada, M1
Bonetti, EP; Burkard, WP; Da Prada, M; Hefti, F; Martin, JR; Müller, RK; Polc, P; Schaffner, R; Scherschlicht, R; Wyss, PC1
Borroni, E; Cesura, AM; Colzi, A; D'Agostini, F; Da Prada, M1

Other Studies

3 other study(ies) available for moclobemide and 2h-benzo(a)quinolizin-2-ol, 2-ethyl-1,3,4,6,7,11b-hexahydro-3-isobutyl-9,10-dimethoxy-

ArticleYear
Brain microdialysis in rats: a technique to reveal competition in vivo between endogenous dopamine and moclobemide, a RIMA antidepressant.
    Psychopharmacology, 1992, Volume: 106 Suppl

    Topics: 2H-Benzo(a)quinolizin-2-ol, 2-Ethyl-1,3,4,6,7,11b-hexahydro-3-isobutyl-9,10-dimethoxy-; 3,4-Dihydroxyphenylacetic Acid; Animals; Benzamides; Binding, Competitive; Brain Chemistry; Dialysis; Dopamine; Male; Moclobemide; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neurons; Rats; Rats, Inbred Strains; Thiazoles

1992
Pharmacological profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A.
    The Journal of pharmacology and experimental therapeutics, 1989, Volume: 248, Issue:1

    Topics: 2H-Benzo(a)quinolizin-2-ol, 2-Ethyl-1,3,4,6,7,11b-hexahydro-3-isobutyl-9,10-dimethoxy-; Animals; Antidepressive Agents; Avoidance Learning; Behavior, Animal; Benzamides; Blood Pressure; Cats; Dose-Response Relationship, Drug; Male; Mice; Moclobemide; Monoamine Oxidase Inhibitors; Motor Activity; Rats; Salivation; Sleep, REM; Stereotyped Behavior; Tyramine

1989
Monoamine oxidase-A inhibitors and dopamine metabolism in rat caudatus: evidence that an increased cytosolic level of dopamine displaces reversible monoamine oxidase-A inhibitors in vivo.
    The Journal of pharmacology and experimental therapeutics, 1993, Volume: 265, Issue:1

    Topics: 2H-Benzo(a)quinolizin-2-ol, 2-Ethyl-1,3,4,6,7,11b-hexahydro-3-isobutyl-9,10-dimethoxy-; Animals; Benzamides; Biogenic Monoamines; Caudate Nucleus; Cytosol; Dopamine; Male; Moclobemide; Monoamine Oxidase Inhibitors; Piperidines; Rats; Serotonin; Tetrodotoxin

1993